

# KYOTO 2024

Advancing Research &  
Patient Care



3<sup>RD</sup> REGIONAL SYMPOSIUM ON  
**MYELODYSPLASTIC  
SYNDROMES**

15-16 MARCH 2024 | KYOTO, JAPAN

## MINI PROGRAM



# We Are THE MDS FOUNDATION



## Providing Professional Resources and Patient Support

MDS Foundation supports and educates patients, their communities, and healthcare providers, and contributes to innovative research in the fields of MDS and its related continuum of diseases to better diagnose, control and ultimately cure these diseases.



**Centers of Excellence**



**Professional Learning Center**



### Professional Resources

- Podcasts
- Webinars
- International Congress
- Regional Symposia
- IPSS-R & IPSS-M Calculators



### MDS Patient Resources

- Patient Podcasts
- Patient Webinars
- Patient Forums
- Free Resources on our website
- Referrals to our COEs


Scan the  
QR codes for  
additional information:



PROFESSIONAL  
MEMBERSHIP



MDSF  
HOME PAGE



## GENERAL INFORMATION

### CONGRESS VENUE

ICC Kyoto  
Takaragaike, Sakyo-ku, Kyoto 606-0001 Japan  
TEL +81-75-705-1229

### OPENING HOURS

DATE	REGISTRATION
Friday, 15 March	08:00 - 17:00
Saturday, 16 March	08:00 - 16:45

### WI-FI

Free WiFi will be available at all Symposium areas.

**WiFi Network: MDSR-2024 | Password: mdsr-2024**

### JOURNAL

Symposium abstracts will be published post-regional symposia in the *Leukemia Research Reports*.

### NAME BADGES

Upon registration, you will receive your name badge. You are kindly requested to wear your badge during all Symposium sessions and events.

### GUEST ATTENDANCE POLICY

All event activities (including educational sessions, meal functions, exhibition area, etc.) are exclusively reserved for registered attendees. Non-registered guests (including children, family members, colleagues, etc.) are not allowed in any of the event areas.

### REFRESHMENTS

Coffee and lunch will be served in the poster area at the times indicated in the Scientific Program.



## NETWORKING EVENT

### WELCOME COCKTAIL

Friday, 15 March, 17:30 – 19:00

Join us for the Welcome Cocktail where you can network with colleagues from around the world in a relaxed environment.

All registered Symposium participants are invited to attend.

## SAFETY AND SECURITY

Please do not leave any bags or suitcases unattended at any time, whether inside or outside session halls.

## LIABILITY AND INSURANCE

The Organizers cannot accept liability for personal injury or damage involving persons and property during the symposium. Participants are advised to take out their own personal travel and health insurance for their trip.

## INFORMATION FOR SPEAKERS

All speakers must check in with the technician at the session Hall at least 1 hour before the start of their session.

- Please note that the computer in the session Hall is supplied with Office 2019 (at least) and the native ratio of the projection on the screen in the Hall is 16:9.
- If you include video clips in your PowerPoint presentation, check with the technician if the sound and picture from the video are transmitted well to avoid technical issues.

### *Important Note for Macintosh Users*

To use MAC presentations on a PC compatible computer, please note that you need to prepare it according to the instructions below, before taking it to the room:

- Convert it to PowerPoint or PDF.
- Use a common font, such as Arial, Times New Roman, Verdana etc. (Special characters might be changed to a default font on a PowerPoint-based PC).
- Insert the images as JPG files (and not TIF, PNG or PICT – these images will not be visible on a PowerPoint based PC).



## POSTER BOARDS

The Poster Presentations are an important part of the Scientific Program and an invaluable opportunity for the exchange of ideas and updates on new research. Please mount your poster according to the below schedule:

**Mounting:** 15 March 09:00 – 11:40

**Removing:** 16 March 15:40 – 16:30

\*The organizers cannot take responsibility for posters that have not been removed by the above-stated time.

We recommend Presenters stand beside their poster during Poster Viewing and breaks at the times indicated in the Scientific Program.

Please ask at the poster help desk onsite for your poster board number.


## SYMPOSIUM ORGANIZERS



Rue François-Versonnex 7,  
1207 Geneva, Switzerland  
Tel: +41 22 501 7420  
Email: [mdsr24@kenes.com](mailto:mdsr24@kenes.com)



## VENUE FLOOR PLAN



Novartis Pharma K.K.



## 新しい発想で医療に貢献します

ノバルティスのミッションは、より充実した、  
すこやかな毎日のために、新しい発想で医療に貢献することです。  
イノベーションを推進することで、  
治療法が確立されていない疾患にも積極的に取り組み、  
新薬をより多くの患者さんにお届けします。

 NOVARTIS

ノバルティス ファーマ株式会社

<http://www.novartis.co.jp/>



## PROGRAM AT A GLANCE

**Friday, 15 March 2024**

Annex Hall

08:30 - 09:00	<b>Registration &amp; Gathering</b>
09:00 - 09:10	<b>Opening Ceremony</b> Stephen Nimer (USA), Seishi Ogawa (Japan)
09:10 - 10:25	<b>Classification, Prognostification</b> Chairs: Elsa Bernard (USA), Hideki Makishima (Japan)  09:10 - 09:35: <b>Molecular classification, molecular prognostification</b> , Elsa Bernard (USA)  09:35 - 10:00: <b>Validation of IPSS-M &amp; molecular classification</b> , Jaroslaw Maciejewski (USA)  10:00 - 10:25: <b>Treatment for MDS with mTP53 / DEC+ VENET?</b> , Naval Daver (USA)
10:25 - 10:50	<b>Coffee Break, Poster Viewing</b>
10:50 - 11:15	<b>Lecture: WHO 2022 &amp; ICC, others</b> Chair: Takahiro Suzuki (Japan)  <b>Review of the two (and more) classifications</b> , Rafael Bejar (USA)
11:15 - 11:40	<b>Lecture: VEXAS Syndrome</b> Chair: Hironori Harada (Japan)  <b>VEXAS syndrome</b> , David Beck (USA)



11:40 - 13:30	<p><b>Current Findings and Unmet Medical Needs in Higher-Risk MDS</b> <b>Abbvie Industry Symposium</b> (11:40 - 12:40) Chair: Hitoshi Kiyoi (Japan)</p> <p>11:40 - 12:40: <b>Current findings and unmet medical needs in higher-risk MDS</b>, Ken Ishiyama (Japan)</p>	Lunch Break, Poster Viewing
13:30 - 14:40	<p><b>Clonal Hematopoiesis/Inflammation</b> Chair: Shigeru Chiba (Japan)</p> <p>13:30 - 13:55: <b>Risk of CCUS</b>, Mario Cazzola (Italy)</p> <p>13:55 - 14:20: <b>CH and non-hematological diseases/inflammation</b>, Benjamin Ebert (USA)</p> <p>14:20 - 14:40: <b>CH among A-bomb survivors</b>, Masataka Taguchi (Japan)</p>	
14:40 - 15:00	Coffee Break, Poster Viewing	
15:00 - 15:25	<p>Lecture: <b>Response Criteria</b> Chair: Akifumi Takaori (Japan)</p> <p><b>New response criteria for MDS</b>, Amer Zeidan (USA)</p>	
15:25 - 16:15	<p><b>Clinical / Lower Risk MDS-1</b> Chairs: Kinuko Mitani (Japan), Eva Hellström-Lindberg (Sweden)</p> <p>15:25 - 15:50: <b>Overview of the treatment for LR-MDS</b>, Eva Hellström-Lindberg (Sweden)</p> <p>15:50 - 16:15: <b>SF3B1</b>, Michaela Fontenay (France)</p>	
16:15 - 17:20	<p><b>Clinical / Lower Risk MDS-2/Tx</b> Chairs: Kinuko Mitani (Japan), Eva Hellström-Lindberg (Sweden)</p> <p>16:15 - 16:35: <b>Darbepoetin</b>, Kinuko Mitani (Japan)</p> <p>16:35 - 17:00: <b>Luspatercept/ new era for LR-MDS Tx</b>, Uwe Platzbecker (Germany)</p> <p>17:00 - 17:20: <b>Immunosuppressive therapy</b>, Kohei Hosokawa (Japan)</p>	



**Saturday, 16 March 2024**

Annex Hall

08:30 - 09:00	<p>Lecture: <b>Morphology</b> Chair: Tomoya Maeda (Japan)</p> <p><b>Dysplasia and low risk situations (ICUS, CCUS, CHIP)</b>, John Bennett (USA)</p>
09:00 - 09:50	<p><b>Future Diagnostics</b> Chairs: Torsten Haferlach (Germany), Toshio Kitamura (Japan)</p> <p>09:00 - 09:25: <b>Genetic and clinical diagnosis based on bone marrow cell morphology</b>, Oscar Brück (Finland)</p> <p>09:25 - 09:50: <b>Use AI for diagnosis, etc.</b> Torsten Haferlach (Germany)</p>
09:50 - 10:10	Coffee Break, Poster Viewing
10:10 - 11:20	<p><b>Germline Predisposition</b> Chairs: Marcin Wlodarski (USA), Junko Takita (Japan)</p> <p>10:10 - 10:35: <b>DDX41</b>, Carmelo Gurnari (USA)</p> <p>10:35 - 11:00: <b>GATA2/SAMD9 genetic predisposition</b>, Marcin Wlodarski (USA)</p> <p>11:00 - 11:20: <b>JMML etc.</b>, Hideki Muramatsu (Japan)</p>
11:20 - 12:00	<p><b>Case Discussion</b> (2 cases) Moderator: Moshe Mittelman (Israel)</p> <p>Panel: Rafael Bejar (USA), Amer Zeidan (USA), Yasushi Miyazaki (Japan)</p>



12:00 - 13:30	<p><b>Impact of Anemia in MDS and New Treatment Option</b>  <b>BMS Industry Symposium</b>  (12:15 - 13:15)  Chair: Kinuko Mitani (Japan)</p> <p>12:15 - 12:20: <b>Opening remarks</b>, Kinuko Mitani (Japan)</p> <p>12:20 - 12:40: <b>Impact of anemia in MDS</b>, Matteo Giovanni Della Porta (Italy)</p> <p>12:40 - 13:00: <b>Review of luspatercept data on LR-MDS</b>, Guillermo Garcia-Manero (USA)</p> <p>13:00 - 13:15: <b>Panel discussion, Q&amp;A, closing remarks</b>, All</p>	Lunch Break, Poster Viewing
13:30 - 15:20	<p><b>Clinical /Higher Risk MDS</b>  Chair: Hideo Harigae (Japan)</p> <p>13:30 - 13:55: <b>Overview of the treatment for HR-MDS</b>, Pierre Fenaux (France)</p> <p>13:55 - 14:20: <b>New drugs including Abs and BCL2-inhibitor for HR-MDS</b>, Guillermo Garcia-Manero (USA)</p> <p>14:20 - 14:40: <b>AZA Tx</b>, Yasuhito Nannya (Japan)</p> <p>14:40 - 15:00: <b>CLK inhibitor</b>, Seishi Ogawa (Japan)</p> <p>15:00 - 15:20: <b>Transplantation or practical Tx for HR-MDS in Japan</b>, Kensuke Usuki (Japan)</p>	
15:20 - 15:40	Coffee Break, Poster Viewing	
15:40 - 16:30	<p><b>MDS/MPN</b>  Chairs: Eric Solary (France), Takahiro Maeda (Japan)</p> <p>15:40 - 16:05: <b>CMML/clinical progress</b>, Raphael Itzykson (France)</p> <p>16:05 - 16:30: <b>CMML molecular pathogenesis</b>, Eric Solary (France)</p>	
16:30 - 16:45	<p><b>Closing Ceremony</b>  Stephen Nimer (USA); Yasushi Miyazaki (Japan)</p>	



## POSTERS

**P001 THE PROGNOSTIC IMPACT OF ERYTHROID DYSPLASIA IN APLASTIC ANEMIA AND MYELODYSPLASTIC NEOPLASMS WITH SINGLE-LINEAGE DYSPLASIA**

Tomoya Maeda, Akira Matsuda, Junya Kanda, Hiroshi Kawabata, Takayuki Ishikawa, Kaoru Tohyama, Akira Kitanaka, Kayano Araseki, Kei Shimbo, Tomoko Hata, Takahiro Suzuki, Hidekazu Kayano, Kensuke Usuki, Maki Shindo-Ueda, Nobuyoshi Arima, Masaharu Nohgawa, Akiko Ohta, Shigeru Chiba, Yasushi Miyazaki, Shinji Nakao, Keiya Ozawa, Shunya Arai, Mineo Kurokawa, Akifumi Takaori-Kondo, Kinuko Mitani

**P002 DIAGNOSTIC UTILITY OF ALDEHYDE DEGRADATION DEFICIENCY SYNDROME USING PROTEOMIC ANALYSIS**

Manabu Wakamatsu, Hideki Muramatsu, Hironori Sato, Masaki Ishikawa, Daisuke Nakajima, Ryo Konno, Yusuke Kawashima, Motoharu Hamada, Yusuke Okuno, Osamu Ohara, Yoshiyuki Takahashi

**P003 MACHINE-LEARNING-BASED PREDICTIVE CLASSIFIER FOR BONE MARROW FAILURE SYNDROME USING COMPLETE BLOOD COUNT AND CELL POPULATION DATA**

Jeongmin Seo, Chansub Lee, Youngil Koh, Choong Hyun Sun, Jong-Mi Lee, Hongyul An, Myungshin Kim

**P004 A META-ANALYSIS OF COMPLICATED CASES OF INFLAMMATORY BOWEL DISEASE AND BONE MARROW FAILURE SYNDROME IN JAPAN**

Takeshi Yagi, Hideki Kumagai, Akira Shimada

**P005 CLINICAL CHARACTERISTICS AND OUTCOMES OF MYELODYSPLASTIC NEOPLASMS AND ACUTE MYELOID LEUKEMIA WITH MECOM REARRANGEMENT: RESULTS FROM A NATIONWIDE MULTICENTER STUDY**

Chantana Polprasert, Chantiya Chanswangphuwana, Weerapat Owattanapanich, Smith Kungwankiattichai, Ekarat Rattarittamrong, Thanawat Rattanathammethee, Adisak Tantiworawit, Wasitthep Limvorapitak, Supawee Saengboon, Pimjai Niparuck, Teeraya Puavilai, Jakrawadee Julamane, Pirun Saelue, Chinadol Wanitpongpun, Chajchawan Nakhakes, Kannadit Prayongratana, Ekapun Karopongse, Ponlapat Rojnuckarin, Chantrapa Sriswasdi

**P006 PROVIDING TIMELY PATIENT-CENTERED MOLECULAR DIAGNOSTIC TESTING FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA: A QUALITY IMPROVEMENT STUDY**

Aatif Qureshi, Jenny Ho, Laila Schenkel, Benjamin Chin-Yee, Uday Deotare, Anahita Meybodi, Lalit Saini, Bekim Sadikovic, Ian Chin-Yee



**P007 MITOCHONDRIAL FRAGMENTATION IS A NEW THERAPEUTIC TARGET AND DIAGNOSTIC CRITERIA FOR MYELOYDYSPLASTIC SYNDROMES**

Yasushige Kamimura-Aoyagi, Yuka Harada, Kosuke Nomura, Natsumi Matsunuma, Kanako Yuki, Hiroki Kobayashi, Yoshihiro Hayashi, Atsushi Hijikata, Hironori Harada

**P008 PATHOGENIC MECHANISMS OF DDX41 MUTATIONS IN THE DEVELOPMENT OF MYELOID MALIGNANCIES**

Ayana Kon, Masahiro Nakagawa, Azumi Tomita, Keisuke Kataoka, Nobuyuki Kakiuchi, Hideki Makishima, Manabu Nakayama, Haruhiko Koseki, Yasuhiro Nannya, Seishi Ogawa

**P009 CYTOGENOMIC PROFILING OF LARGE COHORT OF INDIAN MYELOYDYSPLASTIC SYNDROMES**

Nehakumari Maurya, Chandrakala Shanmukhaiah, Manisha Madkaikar, Babu Rao Vundinti

**P010 CLINICAL IMPLICATIONS OF COPY NUMBER ALTERATION DETECTION USING PANEL-BASED NEXT-GENERATION SEQUENCING DATA IN MYELOYDYSPLASTIC SYNDROME**

Seung-Hyun Jung, Yeun-Jun Chung

**P011 THE ROLE OF LET-7/HMGA2 LINKAGE IN THE PATHOGENESIS AND PROGNOSIS OF MYELOYDYSPLASTIC NEOPLASMS**

Dimitra Vlachopoulou, Christina-Nefeli Kontandreopoulou, Panagiotis T. Diamantopoulos, Stavroula Syriopoulou, Christos Stafylidis, Panagiota Katsiampoura, Athanasios Galanopoulos, Maria Dimou, Panayiotis Panayiotidis, Nora-Athina Viniou

**P012 HAPLOINSUFFICIENCY OF TIE2 IN MUTATED BLOOD CELLS SUPPRESS ANGIOGENESIS IN THE BONE MARROW AND INHIBIT PROGRESSION OF MDS**

Mayumi Hirayama, Yuichiro Arima, Toshio Suda, Goro Sashida

**P013 CLINICAL CHARACTERISTICS AND OUTCOME OF MYELOYDYSPLASTIC SYNDROMES: A SINGLE CENTER STUDY IN THAILAND**

Theerin Lanamtieng, Chinadol Wanitpongpun, Nattiya Teawtrakul

**P014 SIGNATURES OF SOMATIC GENETIC RESCUE IN SAMD9/9L SYNDROMES: DIAGNOSTIC AND PROGNOSTIC UTILITY**

Nathan Gray, Michelle Boals, Sara Lewis, Masanori Yoshida, Sushree Sahoo, Marcin Wlodarski

**P015 KINOME EXPRESSION PROFILING FOR RISK STRATIFICATION OF MYELOYDYSPLASTIC SYNDROMES**

Chi-Yuan Yao, Chien-Chin Lin, Yu-Hung Wang, Chein-Jun Kao, Cheng-Hong Tsai, Hsin-An Hou, Hwei-Fang Tien, Chia-Lang Hsu, Wen-Chien Chou



**P016 DISTINCT PATHOGENESIS OF CLONAL HEMATOPOIESIS REVEALED BY SINGLE-CELL MULTI-OMICS SEQUENCING**

Masahiro Nakagawa, Ryosaku Inagaki, Yutaka Kuroda, Yasuhito Nannya, Masanori Motomura, Ayana Kon, Lanying Zhao, Yotaro Ochi, June Takeda, Xingxing Qi, Koji Okazaki, Akinori Yoda, Nobuyuki Kakiuchi, Hideki Makishima, Shuichi Matsuda, Seishi Ogawa

**P017 KRAS MOSAIC MUTATION AND ITS TISSUE SPECIFICITY IN JUVENILE MYELOMONOCYTIC LEUKEMIA**

Nao Takasugi, Aiko Sato, Katsuyoshi Koh, Atsuko Nakazawa, Motohiro Kato

**P018 DDX41 MUTATIONS DEFINE A DISTINCT SUBTYPE OF MYELOID NEOPLASMS**

Hideki Makishima

**P019 GENETIC LANDSCAPE OF MYELOID NEOPLASMS IN PATIENTS WITH FANCONI ANEMIA**

Kenichi Yoshida, Miharu Yabe, Nobuyuki Kakiuchi, Minoru Takata, Kotoe Katayama, Seiya Imoto, Seishi Ogawa, Hiromasa Yabe

**P020 TPO AGONIST RESCUED DEVELOPMENTAL HEMATOPOIETIC STEM CELL IN HEREDITARY BONE MARROW FAILURE SYNDROME**

Makiko Mochizuki, Ayako Nakamura-Ishizu

**P021 PHASE 3B STUDY DESIGN: COMPARING TREATMENT PREFERENCE BETWEEN ORAL DECITABINE/CEDAZURIDINE AND AZACITIDINE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME, LOW-BLAST ACUTE MYELOID LEUKAEMIA, OR CHRONIC MYELOMONOCYTIC LEUKAEMIA**

Anoop Enjeti, Chun Fong, Taliesha Paine, Francesco Castaldi, Greg Van Wyk, Richard Walton, Harold Keer

**P022 NK-CELLS TRAFFIC TO THE BONE MARROW AS A POTENTIAL IMMUNOLOGICAL MECHANISM OF ACTION OF HYPOMETHYLATING AGENTS FOR HIGH-RISK MDS AND AML**

Junshik Hong, Rahul Ramaswamy, Suji Min, Jihyun Park, Carly Fielder, Qianni Hu, Sung-Soo Yoon, Tae Kon Kim

**P023 LUSPATERCEPT IN TRANSFUSION-DEPENDENT MYELODYSPLASTIC SYNDROMES: REAL WORLD DATA**

Yuemin Gong, Lili Zhou, Ting Zhang, Dan Xu, Yanwen Zhang, Jinning Shi, Jianyong Li, Guangsheng He



**P024 MITOTIC PERTURBATION IS A KEY MECHANISM OF ACTION OF DECITABINE IN MYELOID TUMOR TREATMENT**

Tomohiro Yabushita, Takumi Chinen, Daiju Kitagawa, Toshio Kitamura, Susumu Goyama

**P025 EFFICACY AND SAFETY OF LUSPATERCEPT VERSUS EPOETIN ALFA IN ERYTHROPOIESIS-STIMULATING AGENT (ESA)-NAIVE PATIENTS WITH TRANSFUSION-DEPENDENT LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS): FULL ANALYSIS OF THE COMMANDS TRIAL**

Guillermo Garcia-Manero, Uwe Platzbecker, Valeria Santini, Amer Zeidan, Pierre Fenaux, Rami Komrokji, Jake Shortt, David Valcarcel, Anna Jonasova, Sophie Dimicoli-Salazar, Ing Soo Tiong, Chien-Chin Lin, Jiahui Li, Jennie Zhang, Ana Carolina Giuseppi, Sandra Kreitz, Veronika Pozharskaya, Karen Keeperman, Shelonitda Rose, Thomas Prebet, Andrius Degulys, Stefania Paolini, Thomas Cluzeau, Matteo Giovanni Della Porta

**P026 THREE CASES OF TP53 BIALLELIC-MUTATED AML/MDS BRIDGED TO ALLO-HSCT BY AZA/VEN THERAPY**

Tomoaki Ueda, Kentaro Fukushima, Yasuhito Nannya, Akihisa Hino, Masataka Hamada, Yo Mizutani, Emiko Mizuta, Chihiro Hasegawa, Yuta Yamaguchi, Ryumei Kurashige, Ritsuko Nakai, Shinsuke Kusakabe, Michiko Ichii, Jiro Fujita, Naoki Hoson



**SPONSORS**

**ACKNOWLEDGEMENTS**

**SILVER SPONSOR**





**GENERAL SPONSORS**





**NAKATANI FOUNDATION**  
for advancement of measuring technologies in biomedical engineering



**NIPPON SHINYAKU CO., LTD.**



**NOVARTIS**



**sysmex**


Together for a better  
healthcare journey



**NIPPON SHINYAKU CO., LTD.**

# A new way of life

Tackling intractable diseases  
with our proprietary technologies,  
giving hope to one life at a time.  
Unique functional foods  
to make a healthy life for all.  
A new way of life for a new era.





**NOTES**



## NOTES

This Mini Program is supported by



Advancing Research & Patient Care

The 18<sup>th</sup> International Congress on  
**Myelodysplastic  
Syndromes**

Rotterdam, The Netherlands  
7-10 May 2025

Save  
the  
Date



See you in  
**Rotterdam**  
2025

Join international MDS experts to learn about the latest advances, discoveries, basic and translational research, and MDS diagnosis, prognosis, and management.